These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12695270)

  • 1. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
    Malcolm C; Marrie TJ
    Arch Intern Med; 2003 Apr; 163(7):797-802. PubMed ID: 12695270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
    Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of symptom resolution in patients with community-acquired pneumonia.
    Marrie TJ; Lau CY; Wheeler SL; Wong CJ; Feagan BG
    Clin Infect Dis; 2000 Dec; 31(6):1362-7. PubMed ID: 11096003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
    Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
    Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and ambulatory treatment of patients with community-acquired pneumonia: variability of complementary tests and study of the effectiveness of roxithromycin. Study Group on Ambulatory Treatment of Community-Acquired Pneumonia (NACTA)].
    Rev Clin Esp; 1999 Nov; 199(11):700-4. PubMed ID: 10638232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
    Mykietiuk A; Carratalà J; Fernández-Sabé N; Dorca J; Verdaguer R; Manresa F; Gudiol F
    Clin Infect Dis; 2005 Mar; 40(6):794-9. PubMed ID: 15736010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors.
    Schouten JA; Hulscher ME; Kullberg BJ; Cox A; Gyssens IC; van der Meer JW; Grol RP
    J Antimicrob Chemother; 2005 Sep; 56(3):575-82. PubMed ID: 16049096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuity of antibiotic therapy in patients admitted from the emergency department.
    Shah MN; Schmit J; Croley WC; Meltzer D
    Ann Emerg Med; 2003 Jul; 42(1):117-23. PubMed ID: 12827131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
    Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
    Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli.
    Falguera M; Carratalà J; Ruiz-Gonzalez A; Garcia-Vidal C; Gazquez I; Dorca J; Gudiol F; Porcel JM
    Respirology; 2009 Jan; 14(1):105-11. PubMed ID: 18699803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
    Mokabberi R; Haftbaradaran A; Ravakhah K
    J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
    Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
    An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of emergency department crowding on time to antibiotics in patients admitted with community-acquired pneumonia.
    Fee C; Weber EJ; Maak CA; Bacchetti P
    Ann Emerg Med; 2007 Nov; 50(5):501-9, 509.e1. PubMed ID: 17913300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
    Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
    Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of health care resource utilization after macrolide treatment failure: results from a large, population-based cohort with acute sinusitis, acute bronchitis, and community-acquired pneumonia.
    Wu JH; Howard DH; McGowan JE; Frau LM; Dai WS
    Clin Ther; 2004 Dec; 26(12):2153-62. PubMed ID: 15823779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.